Traverse is building the largest known proprietary atlas of blood-brain-barrier transporters — pairing Andrew Yang’s UCSF/Gladstone molecular map of the human BBB with AI-driven binder design and wet-lab validation — to break the delivery bottleneck that gates the entire CNS therapeutics market. The wedge is scope: Denali and the recently-acquired Aliada each ride one or two receptors (transferrin, CD98); Traverse claims ~65 candidate delivery pathways from a deorphanization sweep pairing hundreds of blood proteins against 400+ BBB receptors, giving it optionality to route different cargoes through different doors.
Yang was named the 2026 Sobrato Prize laureate in Neuroscience for the underlying BBB mapping work Web. Per the 2025-10-01 call, one major pharma that previously worked with Yang’s lab is engaged and a second is under CDA; per the 2026-03-02 update from CEO Rob Williamson, Eli Lilly “is still there wanting to invest.” BEVC led the $1.5M pre-seed and has committed to keep the company funded through the priced Seed. SH committed $500K via StoryHouse Fund II on an uncapped SAFE with 15% discount ahead of the Seed, alongside BEVC.
The narrow “BBB drug delivery” category is a modest $2.66B by 2030 Web, but that number understates the prize: a BBB-crossing platform is a shovel for the far larger CNS therapeutics market — Alzheimer’s, Parkinson’s, MS, ALS and brain oncology, all indications the team explicitly targets Internal. The FDA’s March 2026 accelerated approval of Denali’s AVLAYAH (the first BBB-crossing enzyme replacement therapy using the transferrin receptor) Web is a category-defining validation of receptor-mediated BBB delivery and dramatically de-risks the modality for follow-on entrants.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Traverse Therapeutics | AI + wet-lab atlas of ~65 candidate BBB transport pathways; deorphanization across hundreds of receptor/ligand pairs | ~$2M pre-seed raised; Seed in market | — |
| Denali Therapeutics | TransportVehicle™ platform via transferrin receptor + CD98; enzyme/antibody Fc-engineered shuttles | Public (NASDAQ: DNLI); $3.56B market cap; AVLAYAH FDA-approved Mar 2026 | Traverse has orders-of-magnitude wider pathway menu; Denali has clinical data and an approved drug |
| Aliada Therapeutics | MODEL platform targeting TfR + CD98 for antibodies and genetic medicines | Acquired by AbbVie for $1.4B, Oct 2024 | Same two-receptor limitation as Denali; Aliada was Phase 1 at exit — a direct comp for Traverse’s exit path |
| Roche / Genentech | Brain Shuttle (TfR-based); internal CNS pipeline including trontinemab (Alzheimer’s) | Public; internal program | Traverse is platform-first, Roche is single-asset focused; Roche is a plausible acquirer |
| Voyager Therapeutics | TRACER AAV capsids + non-viral receptor-mediated CNS delivery | Public (NASDAQ: VYGR) | Different modality (AAV/gene therapy tilt); less overlap on biologic delivery |
Moat: the defensibility argument is trade-secret know-how in the transporter atlas plus IP on the engineered binders/linkers Traverse builds against those targets — not on the natural proteins themselves, which are unpatentable. Whether that translates into durable protection is an open question flagged internally (see Risks) Internal.
AbbVie’s $1.4B all-cash acquisition of Phase 1 Aliada in October 2024 — explicitly for its TfR/CD98 BBB-crossing MODEL platform Web — is the cleanest available comp: it establishes that a platform play with promising preclinical/early-clinical BBB data commands nine-to-ten-figure strategic value from CNS pharma. Likely acquirers for Traverse mirror that field: AbbVie, Roche, Biogen (already partnered on Denali’s ATV amyloid-beta program Web), Lilly, Novartis, or Denali itself. On a $500K SAFE entering at the implied $25M working cap, a $1B-scale exit yields ~15–25x gross, with the uncapped structure adding downside if the Seed prices well above that mark.
Email from Rob Williamson updating StoryHouse on Seed fundraising and near-term operating plan four months after the SH investment closed.
Email update from Rob Williamson. Matt — Good to hear from you. I saw the posting and some leads have resulted — so thank you. I am attaching a high level non-con presentation.
Example blurb: Traverse Therapeutics is a CNS and stealth drug delivery start-up founded in the Bay Area using unpublished insights from co-founder Andrew Yang at The Gladstone / UCSF. Using ~$2M of pre-seed funding, the company has built the largest known proprietary Blood Brain Barrier (BBB) transport atlas and knowledge base with advanced AI analytics and drug design. Traverse has uncovered ~65 potential novel pathways for drug delivery into the brain, that will result in more precise drug delivery across all CNS indications, with applicability to areas of significant unmet need such as Alzheimer’s, MS, Parkinson’s, and other CNS diseases. The company is currently manufacturing and testing binders against targets of interest in HT mouse models and, with funding, expects to have 1–2 DCs and 1–2 pharma partnerships over the next 2–3 years.
Regarding financing, we have approached a lot of folks, and do not have a lead (but are working on DCVC or Wing as potential leads). Lilly is still there wanting to invest. Overall, I think we will need more wet lab data (that is compelling), and our current experiment plan will take ~12–14 weeks for a readout. So we may slow down de novo outreach until we get that data, but keep ongoing conversations in process. We have cash through mid-year (perhaps longer) — and are aiming the burn squarely at AI, wet lab data and some IP work.
Specifically for 8VC — we shared materials with Seth Lieblich who said we were too early for 8VC. Back in October 2025 he wanted non-human primate data (NHP) — which we won’t get for at least 18 months from next funding — it is a pretty conservative ask for a seed round.
Structured due-diligence questionnaire response from Rob Williamson (with KH follow-up questions inline). Ships pre-close and captures the company’s own view on achievements, milestones, risks, and competitors.
Document from KH attached. Company Name: Traverse Therapeutics, Inc. (traversetx.com).
Q: What were the company’s two greatest achievements in the last year? A: Formation and establishment of the basic AI platform for mapping multiple pathways into the brain. The deorphanization of hundreds of brain proteins across thousands of blood-brain barrier receptors was a herculean effort that has created significant value.
Q: What two key milestones do you plan to hit in the next 12 months? A: First, we would like to design a library of binders to the target we have identified on the blood-brain barrier. This will likely be an important part of any IP we file in that time frame, which will be another critical milestone.
Q: What are the two risks you are most concerned about? A: Our academic founder’s work will be published and, although it will not necessarily provide a complete and accurate idea of what we are working on, will inform the world about the approach. Other, well-financed entities could quickly develop competitive activities based on this knowledge. We are pursuing IP and advanced insights to counter that a priori to publication.
Q: Who are your competitors? What do you understand about your business that they don’t? A: The most established competitor in the space is Denali. They are focused on two brain delivery mechanisms, transferrin (the general industry standard) and CD98 (a new kid on the block). Our approach is different, in that we understand that many proteins can traverse the blood-brain barrier, and these pathways can have different characteristics that could optimize how a drug is delivered to the brain. So we have a myriad number of better / differentiated potential transferrins in our database right now.
Q: Are the founders subject to any form of equity vesting? A: All grants are 4-year vesting. A portion of the CEO’s stock was triggered on acceptance of the CEO role.
Q: What is the name of the law firm and attorney who is the company’s primary counsel? A: Goodwin, Seth Greenstein (Corporate) and Crowell, Greg Ikonen (BD), and likely WSGR for IP.
Follow-up conversation with Widya Mulyasasmita on Traverse and the BEVC/Bakar ecosystem. Keith attends and files a pointed note on IP strategy weakness after the call.
Traverse Bio-related / Widya with BEVC. Attendees: Widya (BEVC), Miles, Matt, Keith.
Widya (BEVC): Co-founder Berkeley Ventures Capital — PhD bioengineering (Berkeley/Stanford), former McKinsey, J&J innovation, later B Capital Group. Partners with Rowan Chapman (ex-GE Ventures, early PacBio investor). $85M fund investing in Berkeley ecosystem + UCSF overlap. Health sciences (therapeutics, diagnostics, R&D software); deep tech (climate, materials science, data centers). Check sizes $250K–$2M first investment, pre-seed through Series A.
Traverse Therapeutics: BEVC portfolio company targeting BBB delivery. Founded with Andrew Yang (UCSF professor, no postdoc required — “pretty special”). Technology reframes BBB as dynamic interface, not static barrier; catalogued multiple transporters for targeted delivery. Current status: 6 team members (fractional), validating transporters in animal models.
IP strategy: Two Nature publications published, third under review at high-impact journal. Leveraging Andrew’s foundational work + BEVC’s own validation. (KH note: this is not a strategy, this is a recipe for failure — they need to rethink what IP means to them.)
Fundraising: currently pitching “sizable seed round” to VCs. StoryHouse interest: potential co-investment alongside BEVC at early stage.
KH read: She is delightful but, if I read body language right at the end, she may be hesitant to let us invest at the same valuation they did. “IP strategy” for Traverse is neither — they need our help there. Looking forward to diving into this science.